US 11844801
Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
granted A61KA61K31/506A61K45/06
Quick answer
US patent 11844801 (Oral compositions of MK2 pathway inhibitor for treatment of immune conditions) held by Aclaris Therapeutics, Inc. expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Aclaris Therapeutics, Inc.
- Grant date
- Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 64
- CPC classes
- A61K, A61K31/506, A61K45/06, A61K9/0053, A61K9/0056